KRAS and colorectal cancer: The results showed that RGD-p21Ras-scFv reduced p21Ras-GTP expression in all of the above colorectal cancer cell lines, while KRAS (G12C) inhibitor only reduced p21Ras-GTP expression in KRASG12C mutant colorectal cancer cells (Fig. 5A); after analyzing relative protein expression for quantification, our results proved to be statistically significance (Figure Supplementary 3 A).